{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:25:33Z","timestamp":1788837933568,"version":"build-2803163510"},"reference-count":89,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2019.00248","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:36:31Z","timestamp":1572482191000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management"],"prefix":"10.3389","volume":"6","author":[{"given":"Mehdi","family":"Mirsaeidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Barletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn K.","family":"Glassberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,10,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1513\/AnnalsATS.201808-544ED","article-title":"Scleroderma with fibrosing interstitial lung disease: where do we stand?","volume":"15","author":"Meyer","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"B2","first-page":"201","article-title":"History of systemic sclerosis","volume":"148","author":"Armando Laborde","year":"2012","journal-title":"Gac Med Mex"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1183\/09059180.00005512","article-title":"Scleroderma lung disease","volume":"22","author":"Solomon","year":"2013","journal-title":"Eur Respir Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0889-857X(03)00022-X","article-title":"Scleroderma epidemiology","volume":"29","author":"Mayes","year":"2003","journal-title":"Rheum Dis Clin North Am"},{"key":"B6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/BOR.0b013e32834ff2e8","article-title":"Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers","volume":"24","author":"Barnes","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pathophys.2019.05.003","article-title":"Scleroderma: an insight into causes, pathogenesis and treatment strategies","volume":"26","author":"Singh","year":"2019","journal-title":"Pathophysiology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1002\/art.30492","article-title":"Cigarette smoking is not a risk factor for systemic sclerosis","volume":"63","author":"Chaudhary","year":"2011","journal-title":"Arthritis Rheumatol"},{"key":"B10","first-page":"S10","article-title":"Epidemiology of systemic sclerosis in a district of Northern Italy","volume":"29","author":"Lo Monaco","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ajpath.2012.09.007","article-title":"Toll-like receptor 4 signaling augments transforming growth factor-beta responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma","volume":"182","author":"Bhattacharyya","year":"2013","journal-title":"Am J Pathol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3899\/jrheum.180042","article-title":"Ethnic variations in systemic sclerosis disease manifestations, internal organ involvement, and mortality","volume":"46","author":"Al-Sheikh","year":"2019","journal-title":"J Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1568-9972(03)00004-1","article-title":"New insights into the pathogenesis of systemic sclerosis","volume":"2","author":"Tamby","year":"2003","journal-title":"Autoimmun Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1136\/annrheumdis-2018-214865","article-title":"Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease","volume":"78","author":"Valenzi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1089\/wound.2017.0732","article-title":"Toll-like receptor-4 signaling drives persistent fibroblast activation and prevents fibrosis resolution in scleroderma","volume":"6","author":"Bhattacharyya","year":"2017","journal-title":"Adv Wound Care"},{"key":"B17","doi-asserted-by":"publisher","first-page":"E2527","DOI":"10.3390\/ijms18122527","article-title":"Role of microRNAs in TGF-\u03b2 signaling pathway-mediated pulmonary fibrosis","volume":"18","author":"Kang","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1084\/jem.175.5.1227","article-title":"Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts","volume":"175","author":"Yamakage","year":"1992","journal-title":"J Exp Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10067-011-1686-5","article-title":"Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis","volume":"30","author":"Yanaba","year":"2011","journal-title":"Clin Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1002\/art.40862","article-title":"Prevalence, treatment and outcomes of coexistent pulmonary hypertension and interstitial lung disease in systemic sclerosis","volume":"71","author":"Young","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1378\/chest.08-0053","article-title":"Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival","volume":"134","author":"Fischer","year":"2008","journal-title":"Chest"},{"key":"B22","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/art.22532","article-title":"Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors","volume":"57","author":"McNearney","year":"2007","journal-title":"Arthritis Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1378\/chest.114.3.801","article-title":"African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease","volume":"114","author":"Greidinger","year":"1998","journal-title":"Chest"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/art.40130","article-title":"Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1183\/16000617.00002915","article-title":"Interstitial lung disease in systemic sclerosis: where do we stand?","volume":"24","author":"Cappelli","year":"2015","journal-title":"Eur Respir Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1056\/NEJMe1013966","article-title":"Smoking and subclinical interstitial lung disease","volume":"364","author":"King","year":"2011","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1378\/chest.07-2444","article-title":"High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease","volume":"134","author":"Goldin","year":"2008","journal-title":"Chest"},{"key":"B30","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1148\/radiology.188.2.8327704","article-title":"Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage","volume":"188","author":"Remy-Jardin","year":"1993","journal-title":"Radiology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1136\/ard.60.3.281","article-title":"Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis","volume":"60","author":"Fujita","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1378\/chest.08-2572","article-title":"Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia","volume":"136","author":"Song","year":"2009","journal-title":"Chest"},{"key":"B33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1346-8138.2009.00762.x","article-title":"Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis","volume":"37","author":"Hamaguchi","year":"2010","journal-title":"J Dermatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.autrev.2012.05.011","article-title":"Autoantibodies in systemic sclerosis","volume":"12","author":"Mehra","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B35","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.rdc.2014.12.005","article-title":"Interstitial lung disease in scleroderma","volume":"41","author":"Schoenfeld","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"B36","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1378\/chest.13-2626","article-title":"Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review","volume":"146","author":"Winstone","year":"2014","journal-title":"Chest"},{"key":"B37","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/art.22099","article-title":"Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline","volume":"55","author":"Plastiras","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1513\/AnnalsATS.201806-362OC","article-title":"Does systemic sclerosis-associated interstitial lung disease burn out? Specific phenotypes of disease progression","volume":"15","author":"Guler","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1164\/rccm.2106012","article-title":"Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome","volume":"165","author":"Bouros","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.semarthrit.2008.10.009","article-title":"Bronchoalveolar lavage fluid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature","volume":"40","author":"Kowal-Bielecka","year":"2010","journal-title":"Semin Arthritis Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1378\/chest.07-1948","article-title":"Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis","volume":"133","author":"Kinder","year":"2008","journal-title":"Chest"},{"key":"B42","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/art.40815","article-title":"Performance of candidate serum biomarkers for systemic sclerosis-associated interstitial lung disease","volume":"71","author":"Elhai","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/art.22559","article-title":"CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis","volume":"56","author":"Prasse","year":"2007","journal-title":"Arthritis Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3899\/jrheum.080633","article-title":"Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma","volume":"36","author":"Hant","year":"2009","journal-title":"J Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s10067-015-3167-8","article-title":"Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study","volume":"35","author":"Oguz","year":"2016","journal-title":"Clin Rheumatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1378\/chest.108.2.311","article-title":"KL-6: a serum marker for interstitial pneumonia","volume":"108","author":"Kobayashi","year":"1995","journal-title":"Chest"},{"key":"B47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/00005792-200203000-00004","article-title":"Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients","volume":"81","author":"Ferri","year":"2002","journal-title":"Medicine"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3899\/jrheum.180441","article-title":"Cyclophosphamide for systemic sclerosis-related interstitial lung disease: a comparison of scleroderma lung study I and II","volume":"46","author":"Volkmann","year":"2019","journal-title":"J Rheumatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1164\/rccm.201709-1845OC","article-title":"Reliability and minimal clinically important differences of forced vital capacity: results from the scleroderma lung studies (SLS-I and SLS-II)","volume":"197","author":"Kafaja","year":"2018","journal-title":"Am J Respir Crit Care Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1513\/AnnalsATS.201802-079OC","article-title":"Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the scleroderma lung study II","volume":"15","author":"Goldin","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"B51","doi-asserted-by":"publisher","first-page":"R144","DOI":"10.1186\/ar4606","article-title":"Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study","volume":"16","author":"Fraticelli","year":"2014","journal-title":"Arthritis Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/rheumatology\/kes289","article-title":"Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease","volume":"52","author":"Moore","year":"2013","journal-title":"Rheumatology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1002\/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U","article-title":"Severe organ involvement in systemic sclerosis with diffuse scleroderma","volume":"43","author":"Steen","year":"2000","journal-title":"Arthritis Rheumatol"},{"key":"B55","first-page":"S142","article-title":"Performance capacity evaluated using the 6-minute walk test: 5-year results in patients with diffuse systemic sclerosis and initial interstitial lung disease","volume":"33","author":"Rizzi","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e0117829","DOI":"10.1371\/journal.pone.0117829","article-title":"Early stage lung cancer detection in systemic sclerosis does not portend survival benefit: a cross sectional study","volume":"10","author":"Katzen","year":"2015","journal-title":"PLoS ONE"},{"key":"B57","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/rheumatology\/40.1.84","article-title":"Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma","volume":"40","author":"Stratton","year":"2001","journal-title":"Rheumatology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.amjmed.2010.12.009","article-title":"Adverse events during the Scleroderma Lung Study","volume":"124","author":"Furst","year":"2011","journal-title":"Am J Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00296-006-0217-1","article-title":"Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease","volume":"27","author":"Yiannopoulos","year":"2007","journal-title":"Rheumatol Int"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10067-005-1157-y","article-title":"A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis","volume":"25","author":"Nadashkevich","year":"2006","journal-title":"Clin Rheumatol"},{"key":"B64","volume-title":"Cyclosporine, in StatPearls","author":"Tapia","year":"2019"},{"key":"B65","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s10165-010-0403-6","article-title":"Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up","volume":"21","author":"Tochimoto","year":"2011","journal-title":"Mod Rheumatol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1002\/art.27466","article-title":"Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis","volume":"62","author":"Seibold","year":"2010","journal-title":"Arthritis Rheumatol"},{"key":"B67","first-page":"S17","article-title":"Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis","volume":"30","author":"Daoussis","year":"2012","journal-title":"Clin Exp Rheumatol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B70","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/ncprheum0338","article-title":"Interleukin 6: from bench to bedside","volume":"2","author":"Nishimoto","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3899\/jrheum.120725","article-title":"Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis","volume":"40","author":"De Lauretis","year":"2013","journal-title":"J Rheumatol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1182\/blood-2013-05-484782","article-title":"Pomalidomide","volume":"122","author":"Lacy","year":"2013","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3899\/jrheum.161040","article-title":"Pomalidomide in patients with interstitial lung disease due to systemic sclerosis: a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"45","author":"Hsu","year":"2018","journal-title":"J Rheumatol"},{"key":"B75","first-page":"235","article-title":"Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease","volume":"31","author":"Miura","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J Rheumatol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur Respir J"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N Engl J Med"},{"key":"B79","first-page":"75","article-title":"Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS)","volume":"35","author":"Distler","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/art.39021","article-title":"Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study","volume":"67","author":"Bernstein","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.rmed.2013.09.015","article-title":"Survival after lung transplantation in systemic sclerosis. A systematic review","volume":"107","author":"Khan","year":"2013","journal-title":"Respir Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1007\/s00268-005-0017-x","article-title":"Outcomes of lung transplantation in patients with scleroderma","volume":"29","author":"Massad","year":"2005","journal-title":"World J Surg"},{"key":"B83","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1002\/art.22264","article-title":"Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension","volume":"54","author":"Schachna","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1399-0012.2009.00958.x","article-title":"Lung transplantation in patients with scleroderma: case series, review of the literature, and criteria for transplantation","volume":"23","author":"Shitrit","year":"2009","journal-title":"Clin Transplant"},{"key":"B85","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1183\/09031936.00139809","article-title":"Systemic sclerosis and bilateral lung transplantation: a single centre experience","volume":"36","author":"Saggar","year":"2010","journal-title":"Eur Respir J."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"B87","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.bbmt.2018.01.020","article-title":"Autologous hematopoietic stem cell transplantation for systemic sclerosis: a systematic review and meta-analysis","volume":"24","author":"Shouval","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B88","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"B89","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00248\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:36:36Z","timestamp":1572482196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00248\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,31]]},"references-count":89,"alternative-id":["10.3389\/fmed.2019.00248"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2019.00248","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,31]]},"article-number":"248"}}